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Introduction: Near-infrared (NIR) imaging has emerged as a novel imaging modality for
assessing lymphatic function in vivo. While the technique has provided quantitative data
previously unavailable, questions remain in regards to the spatiotemporal capabilities of
the approach. We address three of the more important issues here using the rodent
tail, one of the most widely utilized in vivo model systems in the lymphatic literature.
Specifically we demonstrate (1) the transient vs. steady state response of lymphatics to
tracer injection, (2) the functional characteristics of multiple collecting vessels draining the
same tissue space in parallel, and (3) the long-term consequences of fluorescent tracers
on lymphatic function to repeated functional measurements.
Methods: Rat tails were imaged with NIR and metrics of function were calculated for
both collecting vessels that drain the tail. A nitric oxide donor cream (GTNO) was applied
to the tail. Additionally, two different NIR dyes, indocyanine green (ICG) and LI-COR IRDye
800CW PEG, were utilized for function imaging at the time of initial injection and at 1, 2,
and 4 week follow-up time points after which both draining lymph nodes were harvested.
Results and Discussion: Significant differences were found between the two collecting
vessels such that the vessel first showing fluorescence (dominant) produced enhanced
functional metrics compared to the second vessel (non-dominant). GTNO significantly
reduced lymphatic function in the non-dominant vessel compared to the dominant. ICG
remained visible in the tail for 2 weeks after injection and was accompanied by significant
losses in lymphatic function and enlarged draining lymph nodes. The Licor tracer also
remained visible for 2 weeks. However, the dye produced significantly lower effects on
lymphatic function than ICG, and lymph nodes were not enlarged at any time point,
suggesting that this may be a more appropriate contrast agent for longitudinal lymphatic
imaging.
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INTRODUCTION
The lymphatic vasculature is present in nearly every tissue
of the body to serve essential functions in fluid homeostasis
(Dongaonkar et al., 2009; Nipper and Dixon, 2011), immune
cell trafficking (Swartz et al., 2008; Weber et al., 2013), and lipid
transport (Dixon, 2010), and it has been implicated in the pro-
gression of several diseases (Rockson, 2008; Tammela and Alitalo,
2010). Despite the critical roles that this system performs, very
little is known about the lymphatic vasculature in comparison to
the blood vasculature, which can be attributed, in part, to the his-
toric difficulty associated with imaging lymphatic vessels (Sharma
et al., 2008). With the growing interest in studying lymphatics,
near-infrared (NIR) imaging has emerged as a novel lymphatic
imagingmodality to simultaneously improve spatial resolution to
visualize small initial lymphatics and increase temporal resolution
to capture the dynamic lymphatic pump function responsible for
fluid propulsion.
To date, NIR lymphatic imaging has produced exciting results
quantifying lymphatic transport (Rasmussen et al., 2009), illus-
trating differences in lymphatic architecture between normal
and severe disease cases (Unno et al., 2007), showing differ-
ences in function and architecture due to genetic mutation
(Burrows et al., 2013), and assessing changes in lymphatic func-
tion in response to various manipulations (Weiler et al., 2012;
Blum et al., 2013). However, the technique remains imma-
ture, and the field is still learning to understand and inter-
pret the wealth of data NIR functional lymphatic imaging can
uniquely provide compared to other modalities. In particular,
recent work has suggested functional differences between two
collecting vessels in a rodent hind limb (Proulx et al., 2013),
but no studies have specifically examined the differential trans-
port abilities of multiple collecting vessels draining a single tis-
sue space. Such an analysis is a necessary advancement of NIR
functional lymphatic imaging, which has historically focused
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on quantification of only a single vessel, to better understand
the physiology of draining lymphatic networks at the tissue
level.
Therefore, we have chosen to simultaneously characterize the
two collecting vessels in the rat tail model using NIR lymphatic
imaging. The rat tail provides the simplest model of lymphatic
network drainage for NIR imaging purposes due to the sim-
ple geometry and the consistent position of the two collecting
vessels. Using the rodent tail also allows comparisons to many
previous studies as it has been one of the most widely used
models in lymphatic research, providing insight into basic lym-
phatic physiology and lymph flow (Leu et al., 1994; Weiler
et al., 2012), lymphangiogenesis (Boardman and Swartz, 2003;
Yoon et al., 2003; Goldman et al., 2007; Clavin et al., 2008),
and lymphedema pathology (Rutkowski et al., 2006; Tabibiazar
et al., 2006; Zampell et al., 2012). The results of this char-
acterization will establish a framework by which future lym-
phatic research can be performed using NIR imaging in the tail
model and will enhance our understanding of differential vessel
function.
Additional controversy also remains regarding themost appro-
priate fluorophore for NIR lymphatic imaging. Some studies
are beginning to explore novel probes with higher quantum
yields that specifically target lymphatic vessels (Proulx et al.,
2010, 2013; Davies-Venn et al., 2011), but the most commonly
used probe to date has been indocyanine green (ICG). Despite
the low quantum yield of the molecule, ICG remains the hall-
mark of NIR lymphatic imaging because it is FDA approved
for use in humans and represents the most likely probe for
the development of a point-of-care diagnostic. However, the
literature is mixed regarding the effects of ICG on lymphatic
function.
It has been shown in isolated lymphatic vessels that ICG
inhibits vessel contraction in a dose-dependent manner and con-
tinues to alter function even beyond complete washout from
the vessel (Gashev et al., 2010). Given that near-infrared flu-
orophores have been shown to accumulate in the intracellu-
lar space (Frangioni, 2003), and ICG, in particular, has been
shown to exhibit extremely cumulative cellular uptake (Fickweiler
et al., 1997; Abels et al., 2000), we hypothesize that ICG is
retained in the tissue space and contributes to a decrease in
lymphatic function for an extended period of time following ini-
tial injection. A follow-up study using NIR imaging was unable
to detect changes in lymphatic function after ICG injections
of various concentrations (Aldrich et al., 2012), but the study
only examined this phenomenon at one time point. Therefore,
in this study we will first examine the retention of ICG in
the tissue space of the rat tail and measure lymphatic func-
tion with NIR imaging beyond the duration of retention to
analyze the time course changes in lymphatic function follow-
ing initial ICG injection. For comparison purposes, we will
also perform this analysis with a competing NIR fluorophore,
the LI-COR IRDye 800CW PEG. The results of this study
will contribute to a further characterization of the rat tail
model for NIR lymphatic imaging and will inform future stud-
ies involving multiple, repeat injections of NIR probes in this
model.
METHODS
HARDWARE CONFIGURATION
NIR imaging hardware (Figure 1A) consisted of a 150mW
808 nm laser diode (Thorlabs part no. M9-808-0150) powered
by accompanying diode driver and temperature control boxes to
provide excitation light. A 20◦ beam diffuser (Thorlabs part no.
ED1-C20) was mounted in front of the diode to achieve a uni-
form excitation field. Fluorescence emission centered at 840 nm
was captured using a PIXIS 1024B back-illuminated CCD cam-
era (Princeton Instruments) with an attached Infinity K2/SC
video microscope lens (Edmund Optics) and a bandpass filter
(CW:840 nm, FWHM:15 nm, Omega Optical). NIR images were
recorded via a custom LabVIEW (National Instruments) image
acquisition code.
NIR IMAGING PROCEDURE
Lymphatic function was quantified in vivo in the tail of 6-week-
old female Sprague Dawley rats (Charles River Laboratories,
Wilmington, MA) according to procedures approved by the
Georgia Institute of Technology IACUC Review Board and per-
formed in our laboratory previously (Weiler et al., 2012). All
animals were first anesthetized using an intramuscular injection
of Fentanyl (0.12mg/kg), Droperidol (6mg/kg), and Diazepam
(2.5mg/kg given 10min after Fentanyl/Droperidol). A 10μL flu-
orophore solution of either ICG (Across Organics) pre-mixed
with bovine serum albumin (BSA) (MP Biomedicals, New
Zealand) at a concentration of 150μg/mL ICG and 60mg/mL
BSA or LI-COR IRDye 800CW PEG was then injected intrader-
mally into the tip of the tail for fluorescence imaging (Figure 1B).
An injection volume of 10μL was chosen based upon past suc-
cess in rodent models, so as to not overload the lymphatics
with unnecessary fluid volume while at the same time providing
enough tracer for sufficient detection (Kwon and Sevick-Muraca,
2010; Weiler et al., 2012). The injection was given at an entry
angle of approximately 10◦ to an approximate depth of 1mm
to specifically target the lymphatic vasculature. Care was taken
FIGURE 1 | Near-infrared lymphatic imaging setup. (A) Schematic of
near-infrared imaging hardware. (B) Intradermal tail injection of near-infrared
fluorophore. (C) Example of imaging window 10 cm proximal to injection
site showing fluorescence uptake in the two collecting lymphatic vessels.
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to position the injection as close to the midline of the tail as
possible to avoid favoring one collecting vessel over the other.
The excitation source and the field of view of the CCD emis-
sion detector were centered on the rats’ tail 10 cm downstream
(toward the base of the tail) from the injection site at the tip of
tail (Figure 1C). This location ensured that only the downstream
collecting lymphatics would be visualized so as to avoid any
potential complications from fluorescence uptake by initial lym-
phatics. The small volume of fluid injection and the use of NIR to
enhance tissue penetration ensures that only fluorescence in the
deeper collecting lymphatics is visible downstream of the injec-
tion site. The animals were imaged continuously from the time
of injection until 20min post-injection with a 50ms exposure
time.
QUANTIFYING LYMPHATIC FUNCTION
To evaluate lymphatic function, three parameters were measured:
the time necessary for the bolus injection of ICG to travel the
10 cm distance from injection site to emission recording site
(transport time), the average velocity of the packets traveling
through the field of view of the recording site, and the average
frequency of packets passing through the field of view accord-
ing to previously published methods (Weiler et al., 2012). In
order to characterize the individual function of the two collecting
lymphatic vessels of the rat tail and to quantify the relationship
between them, the three lymphatic function metrics were sepa-
rately calculated for the two vessels of the tail. For the purposes of
this analysis, the vessel in which fluorescence first arrived (marked
by a 20% increase in intensity) was defined as the dominant vessel
and the other vessel was defined as non-dominant. An example of
intensity plots in the two vessels can be seen in Figure 2A. To eval-
uate differences in the transient response to fluid injection from
the steady state response, lymphatic function metrics were calcu-
lated in two separate 100-s segments after injection: the arrival
segment beginning 60 s after fluorescence arrival in each vessel
and the steady state segment beginning 10min after injection. A
representative example of the functional metrics calculated for
both segments in a healthy animal is shown in Figures 2B–E. A
paired, two-tail t-test with a Bonferonni correction for multiple
comparisons was used to test for significance with α = 0.05.
LYMPHATIC IMAGING IN RESPONSE TO NITRIC OXIDE TREATMENT
A nitric oxide (NO) donor cream (glyceryl trinitrate ointment,
GTNO) was applied to the tail as a second experimental con-
dition to observe the effects of NO on the lymphatic func-
tion metrics of the two vessels (n = 3). GTNO was applied to
FIGURE 2 | Representative vessel transport characteristics. (A)
Representative data set showing fluorescence over time for dominant
and non-dominant vessel. Arrival and steady-state segments are
highlighted in the gray boxes. (B) Close-up view of intensity signal
during arrival segment. (C) Close-up view of intensity signal during
steady-state segment. (D) Packet frequency and packet velocity during
arrival segment. (E) Packet frequency and packet velocity during
steady-state segment.
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the whole tail one-minute prior to injection. Lymphatic func-
tion was calculated for both collecting vessels in the same
manner described above. Comparisons between normal and
GTNO-treated animals were checked for significance using an
unpaired, two-tail t-test with a Bonferroni correction and α =
0.05. Significance within the GTNO treatment group was ana-
lyzed using a paired, two-tail t-test with a Bonferroni correction
and α = 0.05.
TIME-COURSE ANALYSIS OF ICG
To characterize the long-term effects of ICG on lymphatic func-
tion, a time course study was performed. Initially, a single 10μL
intradermal ICG injection (150μg/mL ICG and 60mg/mL BSA)
was given in the tip of the tail (n = 4) and fluorescence measure-
ments were taken every 2 days to track ICG retention.
Based upon the results of the retention study, a second study
was performed to monitor changes in lymphatic function dur-
ing the ICG retention period, which is depicted graphically in
Table 1. All animals in this group were given an initial 10μL
intradermal ICG injection (150μg/mL ICG and 600mg/mL BSA)
in the tip of the tail at week 0 and baseline lymphatic function
measurements were recorded for both collecting vessels. The ani-
mals were divided into three treatment groups with follow-up
10μL intradermal ICG injections and functional measurements
at 1, 2, and 4-week time points (n = 4). Follow-up injections
Table 1 | ICG time-course experimental setup.
Week 0 Week 1 Week 2 Week 4
Group 1 Treatment ICG/IR dye
injection
ICG/IR dye
injection
LN harvest
Control BSA
injection
ICG/IR dye
injection
LN harvest
Group 2 Treatment ICG/IR dye
injection
ICG/IR dye
injection
LN harvest
Control BSA
injection
ICG/IR dye
injection
LN harvest
Group 3 Treatment ICG/IR dye
injection
ICG/IR dye
injection
LN harvest
Control BSA
injection
ICG/IR dye
injection
LN harvest
Animals were divided into three groups for follow-up imaging at 1, 2, and 4
weeks. All animals were given a 10µL intradermal injection of either ICG, IR
Dye, or BSA at week 0, and function metrics were recorded as a baseline for
treatment animals. During the follow-up session for each group, the animals
were given a 10µL fluorophore injection for lymphatic function measurements
and lymph nodes were harvested.
were given as close to the original injection site as possible with
particular care to keep the injection at the midline of the tail.
Definitions of dominant and non-dominant vessels were made
based upon week 0 measurements and remained consistently
defined throughout follow-up screenings regardless of follow-
up transport times (although the dominant vessel continued
to produce the fastest transport times in nearly 90% of cases).
Control animals were given a 10μL intradermal BSA injection in
the tip of the tail at week 0 with follow-up 10μL intradermal ICG
injections and functional measurements at the same three time
points (n = 4). Comparisons of function between time points
was checked for significance using a paired, one-tail t-test with
α = 0.05.
A third set of animals was used to observe the effects
ICG on lymph node size. All animals were again given a sin-
gle 10μL intradermal ICG injection in the tip of the tail.
The sciatic lymph node (nearest draining node) was harvested
for both collecting vessels without any additional follow-up
injections at the week 0, 1, 2, and 4 time points (n = 3).
Control animals were given a 10μL intradermal BSA injec-
tion in the tip of the tail and lymph nodes were harvested
at each time point (n = 3) without any follow-up injections.
Lymph node size was calculated using projected two-dimensional
area from microscopy images. We attempted to take fluo-
rescence images to observe ICG retention in the nodes, but
fluorescence was only detectable at the week 0 time point.
Comparisons of lymph node size were checked for significance
using an unpaired, two-tail t-test with a Bonferroni correction
and α = 0.05.
In order to compare the results of ICG to another popu-
lar NIR fluorophore, the same procedure outlined above was
also performed using the LI-COR IRDye 800CW PEG including
retention (n = 4), time course functional measurements (n = 4),
and lymph node harvesting (n = 3).
RESULTS
SPATIAL AND TEMPORAL CHARACTERIZATION OF LYMPHATIC
FUNCTION IN THE TAIL
Figure 2 shows a representative example of fluorescence inten-
sity measurements over time and packet frequency and
velocity measured during the arrival and steady-state seg-
ments. We have denoted the first arrival vessel as domi-
nant and the other as non-dominant. All imaging sessions
showed at least a 2 s difference in fluorescence arrival times
between the two vessels with greater than 70% of cases
showing a difference of 20 s or more. The dominant vessel
nearly always produced higher intensity values than the non-
dominant vessel throughout the imaging session (Figure 2A) and
remained consistent across multiple injections in the majority of
animals.
During the arrival period the dominant vessel exhibited a
rapid increase in fluorescence while the non-dominant vessel
usually produced a more gradual rise in fluorescence. Packet fre-
quency and velocity in both vessels peaked during or shortly after
the arrival stage. The values then tapered off toward a lower,
constant value during the steady-state period with the domi-
nant vessel constantly producing larger or equal frequencies and
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FIGURE 3 | Representative packet frequency and velocity tracings. Representative data set showing (A) average packet frequency and (B) average packet
velocity for the dominant and non-dominant vessel over time.
FIGURE 4 | Lymphatic function metrics in healthy and
GTNO-treated cases. Compiled data for (A) transport time, (B)
packet frequency, and (C) packet velocity for the dominant and
non-dominant vessel during arrival and steady-state segments in
healthy and GTNO-treated animals (n = 3). Error bars represent
standard deviation. ∗p < 0.01.
velocities than the non-dominant vessel (Figures 2D,E, 3). The
dominant vessel produced significantly reduced transport times,
and significantly increased packet frequencies and packet veloci-
ties compared to the non-dominant vessel in the arrival segment,
but there were no significant differences in the three functional
metrics between the two vessels in the steady-state pumping
period (Figure 4). Packet frequencies and packet velocities were
significantly higher during the arrival stage than the steady-state
period in the dominant vessel, but not in the non-dominant
vessel.
DIFFERENTIAL EFFECTS OF NITRIC OXIDE ON LYMPHATIC FUNCTION
The application of GTNO significantly increased transport times
in both vessels compared to healthy animals as we have reported
previously (Weiler et al., 2012), but a much larger increase
was seen in the non-dominant vessel in which transport times
increased nearly 6-fold (Figure 4). NO-mediated vessels also
showed significantly decreased packet frequency and packet
velocity in both vessels during the arrival period and in the
non-dominant vessel during the steady state period.
CONSEQUENCES OF ICG RETENTION ON LYMPHATIC FUNCTION
ICG remained visible (as defined by a signal to noise ratio greater
than 3 dB) in the tissue space for more than 2 weeks after initial
injection (Figure 5). NIR lymphatic function measurements after
follow-up ICG injections of 1 week showed significant reduc-
tions in all three lymphatic function metrics in both vessels
during the arrival and steady state segments (Figure 6). Transport
FIGURE 5 | ICG is retained in tissue space for 2 weeks. (A)
Representative images of the tip of a rat tail at four time points:
immediately following ICG injection (week 0) and 1, 2, and 4 weeks after
injection. (B) Average signal-to-noise ratio (SNR) of ICG in the tip of the rat
tail (n = 4). Dotted line represents limit of detection at 3 dB. Error bars
represent standard deviation.
time remained significantly elevated in the non-dominant vessel
at the week 2 time point. Packet frequency and velocity like-
wise remained elevated in the non-dominant vessel at week 2,
but only during the arrival period. No significant differences in
function were observed at week 4. Control animals did not pro-
duce significant differences in lymphatic function at any time
point.
Lymph nodes were also significantly enlarged in both vessels
at the 1 and 2 week time points with more than a 350% increase
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FIGURE 6 | ICG reduces lymphatic function 1 and 2 weeks after initial
injection. Compiled (A) transport time, packet frequency during (B) arrival
and steady-state (C), and packet velocity during (D) arrival and (E)
steady-state periods for dominant and non-dominant vessels during the four
time points and for the control animals at week 1. Error bars represent
standard deviation. ∗p < 0.05.
in projected two-dimensional area at week 1 and almost a 200%
increase at week 2 (Figure 7). Lymph nodes harvested at week 4
were not significantly enlarged from their baseline values. Control
animals did not produce significant differences in lymph node
size at any time point.
The LI-COR IRDye 800CW PEG likewise remained visi-
ble in the rat collecting lymphatics for approximately 2 weeks.
However, the only function metric observed to be significantly
different during the follow-up sessions was an increased trans-
port time in the non-dominant vessel at week 1. When com-
pared with ICG, the LI-COR dye produced much less severe
effects on lymphatic function at the week 1 and 2 follow-up
time points (Figure 8). The LI-COR dye produced a significantly
lower percent change in transport time in both vessels at week
1 and in the non-dominant vessel in week 2 as compared
to ICG. Similarly for packet frequency, the LI-COR dye pro-
duced a significantly reduced change at the week 1 time point
in both vessels and at the 2 week time point in the non-
dominant vessel as compared to ICG. Additionally, for packet
velocity, the LI-COR dye produced a significantly reduced effect
FIGURE 7 | Draining lymph nodes enlarge 1 and 2 weeks after ICG
injection. (A) Representative microscopy images of sciatic lymph nodes
without injection, 1 week after BSA control injection, and 1 and 2 weeks
after ICG injection. Grid squares = 25mm2. (B) Projected two-dimensional
area of lymph nodes prior to injection, 1 and 2 weeks after ICG injection,
and 1 week after control BSA injection. Data is compiled for both sciatic
lymph nodes at each time point. Error bars represent standard deviation.
∗p < 0.001.
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FIGURE 8 | LI-COR IRDye 800CW PEG reduces lymphatic
function less than ICG. Percent change in (A) transport time,
(B) packet frequency, and (C) packet velocity between initial
measurement and 1 and 2 week follow-up time points for ICG
and LI-COR IRDye 800CW PEG. Error bars represent standard
deviation. ∗p < 0.01.
compared to ICG at the week 1 and 2 time points only in
the non-dominant vessel. Finally, the LI-COR dye did not
produce any significant changes in lymph node size at any
time point.
DISCUSSION
VESSEL TRANSPORT CHARACTERISTICS
The lymphatic vasculature is a complex network of intercon-
nected vessels and nodes whose fluid transport capabilities are
still not well-understood at the tissue level. This study represents
a new effort toward quantifying the differential effects of multiple
collecting lymphatic vessels draining a single tissue space, which
will help to explain how the organ system functions as a whole
in the context of fluid transport. We have provided a new frame-
work for analyzing lymphatic function across multiple vessels to
better assess cumulative lymphatic drainage of the interstitium.
This framework will make NIR imaging more sensitive to lym-
phatic function, which may prove useful in distinguishing subtle
changes between health and disease in the context of lymphatic
research and the development of a point-of-care diagnostic.
Our results revealed that one vessel always produced fluores-
cence before the other with the difference in 10 cm transport time
between the two vessels usually exceeding 20 s. In nearly every
case, the first arrival vessel exhibited higher fluorescence intensity
values, packet frequencies and packet velocities than the second
arrival vessel, although both vessels consistently produced values
in a range consistent with previously reported mesenteric lymph
velocities (Dixon et al., 2006; Kassis, 2012) and packet frequen-
cies and velocities in rat tail lymphatics (Weiler et al., 2012). We
defined the first arrival vessel as dominant and the second arrival
vessel as non-dominant in an effort to describe the observed
difference in function between the two vessels. Importantly, the
dominant vessel remained consistent across multiple injections
in the same animal in the vast majority of cases, suggesting
this phenomenon is repeatable and inherent to the function
of that particular vessel network. Similar differential transport
characteristics were also observed by Proulx et al. in two afferent
collecting vessels of the mouse hind limb (Proulx et al., 2013),
which indicates that our results may not be restricted to simply
the rodent tail model and may be representative of general sys-
temic lymphatic function. Future work will need to be done to
address the relevance of these observations in rodents, to human
lymphatic physiology.
There are several potential explanations for the observation of
differential transport function between the two collecting vessels.
Firstly, it is possible that preferential lymphatic drainage pat-
terns exist such that for a given tissue space, fluid drainage is
the primary responsibility of one single vessel, while any addi-
tional vessels in the area serve as overflow or reserve transport
routes for large fluid loads. Preferential drainage patterns could
be the result of regional variability in the location and distribu-
tion of different lymphatic vessel networks in the tissue space
or the composition and organization of the interstitium at the
injection site such that drainage into one collector over is favored
over the other. Since our repeat injections in the same animal
were performed as close to the original injection site as pos-
sible, either of these two potential explanations could account
for the consistency of the dominant vessel across multiple injec-
tions. Although the utmost care was taken to ensure all injections
were consistently given at the same angle, depth, and location,
there is a substantial degree of inherent variability in the intra-
dermal injection procedure, which could also be contributing
to the observed differences in vessel function by differentially
or inconsistently favoring drainage into one vessel over another.
Furthermore, there were no detectable differences in vessel size
within the spatial resolution limits of our imaging system, but
fluorescence scattering makes accurate measurements of vessel
diameter very difficult in vivo. Thus, it remains unclear whether
subtle differences in vessel depth or vessel diameter may be a
contributing factor favoring transport through one vessel over
the other. Finally, the degree to which nodal resistance may
contribute to the observed results is unknown and could be
significant. Future work should specifically focus on the differ-
ences in function between multiple lymphatic vessels in several
anatomic regions and under various experimental conditions to
better characterize systemic lymphatic transport.
Our results also revealed a transient period during early flu-
orescence arrival in which lymphatic function was generally
enhanced as compared to the subsequent steady-state period. This
observation is not surprising when considering the bolus delivery
and high albumin concentration of our injection. The duration
of the transient arrival period was typically between 2–5minutes,
which is consistent with the small 10μL volume of our injec-
tions and the time kinetics associated with responses to changes
in Starling’s forces observed in the microvasculature (Levick and
Michel, 2010). After the initial response of the lymphatics to
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this change in the local interstitial fluid parameters that gov-
ern filtration, steady-state values of lymphatic transport were
reached. Interestingly, more significant differences in function
were observed between the dominant and non-dominant vessel
during the transient arrival period than the steady-state period.
This is consistent with the method we have utilized to categorize
these two vessels (i.e., the vessel with a shorter arrival time is the
dominant), as the arrival time is a metric that is reflective of ves-
sel function during the initial transient response. Thus, the larger
packet velocities and frequencies in the dominant vessel immedi-
ately after injection explain in part why transport time is shorter
than in the non-dominant vessel.
These observations generally illustrate the importance of using
a consistent framework to quantify lymphatic vessel function
using NIR imaging. That is, we have shown that significant differ-
ences in transport characteristics are obtained by taking measure-
ments during different periods following fluorophore injection or
by quantifying different vessels draining the same tissue space. An
optimal strategy for NIR quantification of vessel function remains
undefined at this point, but future studies should be performed
with careful consideration of the measurement framework, espe-
cially given that the selection of methodology for analysis can
drastically affect results.
EFFECTS OF NITRIC OXIDE
The effects of NO on vessel function further exemplify the impor-
tance of choosing an appropriate framework for transport quan-
tification using NIR imaging. Our previous work showed that
GTNO significantly reduced lymphatic drainage as evaluated by
several function metrics (Weiler et al., 2012), but that analysis
was limited to a single vessel and response time. Analyzing the
effects of GTNO in the context of this more robust two-vessel,
two-time-period framework may begin to provide a more broad
understanding of the effects of NO on cumulative lymphatic
drainage. Specifically, the results indicated that GTNO generally
reduced function in both vessels, but more severely affected the
non-dominant vessel.
The transport time metric, in particular, was very different
between the two vessels after GTNO application. This metric
incorporates extrinsic factors affecting uptake such as interstitial
fluid pressure and matrix resistance as well as intrinsic factors
affecting transport such as vessel contraction. Given that previous
work has shown NO acts on lymphatics by strongly inhibit-
ing vessel contractility (Gashev et al., 2002; Liao et al., 2011),
these results could suggest a difference between the two vessels
in the balance of intrinsic contractions vs. extrinsic factors in
fluid transport following a large fluid load. That is, if preferen-
tial drainage patterns exist as we suspect, the increased interstitial
fluid pressure after bolus injection would drive flow more favor-
ably into the dominant vessel, while the non-dominant vessel
would be forced to rely more exclusively on intrinsic contrac-
tions to transport fluid. The resultant vessel dilation following
GTNO application would severely impair transport in the non-
dominant vessel by inhibiting contractility. However, the effects
would be much less severe in the dominant vessel because dila-
tion would decrease vessel resistance, thus enhancing the effects
of elevated interstitial fluid pressure driving flow into the vessel.
This could help to explain why NOmore significantly affected the
non-dominant vessel, especially in the transport time metric.
Alternatively, these observations could be the result of sec-
ondary effects of NO on lymph formation, which could differ-
entially affect uptake and subsequent transport in the two vessels.
The lymphatic community has recently become very interested
in the modulating effects of NO on lymphatic function in health
and disease (Bohlen et al., 2011; Liao et al., 2011; Scallan and
Davis, 2013), and future work devoted to a more thorough char-
acterization of NO on lymphatic network drainage would be
well-warranted.
EFFECTS OF NIR FLUOROPHORES
In this study, we have shown for the first time with NIR imag-
ing that injection of ICG contributed to long-term decreases
in lymphatic function. The results of the long-term follow-up
screenings revealed that ICG was retained in the local tissue space
for approximately 2 weeks after injection, and lymphatic trans-
port was reduced during this period. There was a fairly dramatic
decrease in function at the 1 week time point in which all met-
rics were reduced in both vessels, but week 2 produced a less
severe reduction in function and was limited exclusively to the
non-dominant vessel. Lymph nodes were also enlarged at 1 and 2
weeks after injection, but interestingly, there was not a significant
difference in size between lymph nodes of the dominant and non-
dominant vessel. Very importantly, control animals in which the
initial injection contained albumin but lacked ICG did not pro-
duce any significant change in function or lymph node size at any
time point. Since the control injections were the same volume and
given in the same manner as the ICG injections, this data suggests
that the observed decreases in lymphatic function following ini-
tial injection of ICG were due to the fluorophore itself rather than
the injection procedure or any other constituent of the injection
solution.
Fortunately, the effects of ICG appear to be reversible since all
of the functional metrics returned to baseline levels in both ves-
sels and lymph nodes returned to normal size at the week 4 time
point. Despite the data showing a functional decrease in lym-
phatic transport after ICG injection, it is difficult to determine
whether the observed effect sizes are substantial enough to war-
rant physiological concern. Although lymph nodes showed signs
of enlargement after ICG injection, the level of hypertrophy was
not nearly as large as the 20- to 30-fold increase in nodal weight
seen in models of chronic inflammation (Ezaki et al., 2001; Baluk,
2005). No detectable edema was observed in the tail of any of the
animals at any point during the time course, which suggests that
ICG does not decrease lymphatic drainage to the point of causing
significant fluid stagnation or inflammation. It does not appear
that ICG needs to be treated as a health concern at least at fre-
quencies that don’t exceed once per month, but care should be
taken in interpreting NIR functional data with this fluorophore,
especially in the context of repeat injections. Repeat injections
with ICG may need to be spaced as far apart as 4 weeks in order
to avoid erroneous measurements in function, although a simi-
lar investigation of time-course effects of ICG in humans would
be valuable for the continued development of a point-of-care
diagnostic.
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The observed decreases in lymphatic function are consistent
with the investigation of ICG in isolated lymphatic vessels by
Gashev et al. (2010). Our result, that reduced function appeared
to coincide with ICG retention, is similar to their observation that
vessel contraction was inhibited even beyond the period of ICG
washout. Gashev et al. was able to show ICG binds to the endothe-
lial cell layer in the isolated vessel setup, but in our study, ICG
was most visibly retained at the injection site. A small amount
of fluorescence was visible in the collecting vessels for 1–2 days
immediately after the injection, but the intensity quickly dropped
below the limit of detection due to scattering effects and a low
concentration of dye. With our imaging system the limit of detec-
tion of ICG in tail collecting vessels is in the micromolar range,
which is consistent with concentrations used by Gashev et al. It
is difficult, therefore, to make strong conclusions from our data
regarding the mechanism by which ICG affected lymphatic func-
tion. At the very least, however, the injection site would have been
constantly releasing small amounts of ICG into the lymphatic ves-
sels over the course of the retention period, which could have
contributed to the long duration of decreased function. Given the
evidence of ICG toxicity with prolonged exposure in the retina
(Ikagawa et al., 2005), it is possible that the decrease in lymphatic
function could also be a result of ICG reported mild toxicity.
One limitation of our study is that we only used one concentra-
tion of ICG for injection. Although the volume of the injection is
very small, the concentration is optimized for fluorescence visual-
ization rather than consideration of vessel function. It is possible
that a more dilute solution, while negatively influencing fluores-
cence intensity, may contribute to shorter retention periods and
have less of a long-term impact on function.
An additional investigation by Aldrich et al. did not detect
a change in lymphatic function in response to ICG injections
(Aldrich et al., 2012), but these results do not necessarily con-
flict with ours and there are several explanations for these results.
Firstly, it should also be noted that our initial baseline readings for
ICG and the LI-COR IRDye 800CW are similar to those reported
by the authors. The principal difference between the two studies
is the time-point of interest after injection. Aldrich et al. exam-
ined lymphatic function effects immediately after injection while
we used this value as a baseline and instead focused on time
course differences 1, 2, and 4 weeks later. Given that ICG has
been shown accumulate in the intracellular space for a period
beyond 24 h (Fickweiler et al., 1997; Abels et al., 2000), time may
be a necessary component for the cumulative dose to affect ves-
sel function. Another difference between our study and that of
Aldrich et al. is the above-mentioned framework used for analy-
sis of NIR imaging. This framework was critical to generating our
results, especially since more profound effects were seen in the
non-dominant vessel and during the arrival period initially after
injection. Finally, our study was performed in the rat tail, while
Aldrich et al. used the mouse inguinal-to-axillary model, and it
remains unclear if and how lymphatic function may vary between
the two regions and the two species.
The functional results of the LI-COR IRDye 800CW PEG pro-
vide an interesting comparison to ICG. The dye produced a mild
decrease in lymphatic function at week 1, but it did not contribute
to a deterioration of function nearly as severe as ICG and did not
affect lymph node size. These results are not meant to indicate
that the LI-COR IRDye is an optimal solution for NIR lymphatic
imaging, although it appears to have less of a long-term effect
on lymphatics than ICG, but rather to illustrate that the choice
of fluorophore impacts NIR lymphatic functional measurements.
Thus, optimizing the tracer of choice to minimize its biological
impact is warranted, particularly in the context of longitudi-
nal lymphatic imaging. The difference in functional response
between ICG and the IRDye may suggest that the chemical
composition and three-dimensional structure of the fluorophore
either directly modulates lymphatic transport or indirectly affects
lymphatic function through eliciting an immune response (Liao
et al., 2011), especially given the observed differential effects on
lymph node size between the two dyes in this study. The NIR lym-
phatic imaging community has been directing research toward
the development and optimization of fluorophores specifically
for the purpose of lymphatic imaging (Proulx et al., 2010, 2013;
Davies-Venn et al., 2011). While these efforts have concentrated
primarily on using dyes with higher quantum yields than ICG or
altering the size of the carrier molecule to optimize lymphatic
uptake, future work in the development of new probes should
also focus on the long-term effects of the dyes on local lymphatic
and immune function. Repeat injections, either in the context
of research or a point-of-care diagnostic will need to have no
effect on lymphatic function in order to obtain meaningful and
consistent results.
ACKNOWLEDGMENTS
This work was partially funded by NIH Grant NHLBI
R00HL091133, the Georgia Tech—Emory Center for
Regenerative Medicine, and the National Science Foundation
Graduate Research Fellowship Program. Any opinion, findings,
and conclusions or recommendations expressed in this material
are those of the authors and do not necessarily reflect the views
of the National Science Foundation. The authors would also like
to acknowledge Dr. Susan Thomas from Georgia Tech for her
assistance with the analysis of lymph nodes in this project.
REFERENCES
Abels, C., Fickweiler, S., Weiderer,
P., Baumler, W., Hofstädter, F.,
Landthaler, M., et al. (2000).
Indocyanine green (ICG) and laser
irradiation induce photooxidation.
Arch. Dermatol. Res. 292, 404–411.
doi: 10.1007/s004030000147
Aldrich, M. B., Davies-Venn, C.,
Angermiller, B., Robinson, H.,
Chan, W., Kwon, S., et al. (2012).
Concentration of indocyanine
green does not significantly influ-
ence lymphatic function as assessed
by near-infrared imaging. Lymphat.
Res. Biol. 10, 20–24. doi: 10.1089/
lrb.2011.0003
Baluk, P. (2005). Pathogenesis of
persistent lymphatic vessel
hyperplasia in chronic airway
inflammation. J. Clin. Invest. 115,
247–257.
Blum, K. S., Proulx, S. T., Luciani,
P., Leroux, J.-C., and Detmar, M.
(2013). Dynamics of lymphatic
regeneration and flow patterns
after lymph node dissection.
Breast Cancer Res. Treat. 139,
81–86. doi: 10.1007/s10549-013-
2537-7
Boardman, K., and Swartz, M. A.
(2003). Interstitial flow as a guide
for lymphangiogenesis. Circ. Res.
92, 801–808. doi: 10.1161/01.RES.
0000065621.69843.49
Bohlen, H. G., Gasheva, O. Y., and
Zawieja, D. C. (2011). Nitric oxide
formation by lymphatic bulb and
valves is a major regulatory com-
ponent of lymphatic pumping.
www.frontiersin.org August 2013 | Volume 4 | Article 215 | 9
Weiler and Dixon NIR lymphatic imaging with ICG
Am. J. Physiol. Heart Circ. Physiol.
301, H1897–H11906. doi: 10.1152/
ajpheart.00260.2011
Burrows, P. E., Gonzalez-Garay, M.
L., Rasmussen, J. C., Aldrich, M.
B., Guilliod, R., Maus, E. A., et al.
(2013). Lymphatic abnormalities
are associated with RASA1 gene
mutations in mouse and man.
Proc. Natl. Acad. Sci. U.S.A. 11,
8621–8626. doi: 10.1073/pnas.
1222722110
Clavin, N. W., Avraham, T., Fernandez,
J., Daluvoy, S. V., Soares, M. A.,
Chaudhry, A., et al. (2008). TGF-
beta1 is a negative regulator of lym-
phatic regeneration during wound
repair. Am. J. Physiol. Heart Circ.
Physiol. 295, H2113–H2127. doi:
10.1152/ajpheart.00879.2008
Davies-Venn, C. A., Angermiller,
B., Wilganowski, N., Ghosh, P.,
Harvey, B. R., Wu, G., et al. (2011).
Albumin-binding domain conju-
gate for near-infrared fluorescence
lymphatic imaging. Mol. Imaging
Biol. 14, 301–314. doi: 10.1007/
s11307-011-0499-x
Dixon, J. B. (2010). Lymphatic lipid
transport: sewer or subway? Trends
Endocrinol. Metab. 21, 480–487. doi:
10.1016/j.tem.2010.04.003
Dixon, J. B., Moore, J. E. Jr., Cote,
G., Gashev, A. A., and Zawieja,
D. C. (2006). Lymph flow, shear
stress, and lympfyte velocity in
rat mesenteric prenodal lymphatics.
Microcirculation 13, 597–610. doi:
10.1080/10739680600893909
Dongaonkar, R. M., Laine, G. A.,
Stewart, R. H., and Quick, C. M.
(2009). Balance point characteriza-
tion of interstitial fluid volume reg-
ulation. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 297, R6–R16. doi:
10.1152/ajpregu.00097.2009
Ezaki, T., Baluk, P., Thurston, G.,
La Barbara, A., Woo, C., and
McDonald, D. M. (2001). Time
course of endothelial cell pro-
liferation and microvascular
remodeling in chronic inflam-
mation. Am. J. Pathol. 158,
2043–2055. doi: 10.1016/S0002-
9440(10)64676-7
Fickweiler, S., Szeimies, R. M., Baumler,
W., Steinbach, P., Karrer, S., Goetz,
A. E., et al. (1997). Indocyanine
green: intracellular uptake and
phototherapeutic effects in vitro.
J. Photochem. Photobiol. B 38,
178–183. doi: 10.1016/S1011-1344
(96)07453-2
Frangioni, J. (2003). In vivo near-
infrared fluorescence imaging. Curr.
Opin. Chem. Biol. 7, 626–634. doi:
10.1016/j.cbpa.2003.08.007
Gashev, A. A., Davis, M. J., and Zawieja,
D. C. (2002). Inhibition of the active
lymph pump by flow in rat mesen-
teric lymphatics and thoracic duct.
J. Physiol. 540, 1023–1037.
Gashev, A. A., Nagai, T., and
Bridenbaugh, E. A. (2010).
Indocyanine green and lym-
phatic imaging: current problems.
Lymphat. Res. Biol. 8, 127–130. doi:
10.1089/lrb.2010.0005
Goldman, J., Conley, K., Raehl, A.,
Bondy, D., Pytowski, B., Swartz,
M. A., et al. (2007). Regulation
of lymphatic capillary regenera-
tion by interstitial flow in skin.
Am. J. Physiol. Heart Circ. Physiol.
292, H2176–H2183. doi: 10.1152/
ajpheart.01011.2006
Ikagawa, H., Yoneda, M., Iwaki, M.,
Isogai, Z., Tsujii, K., Yamazaki,
R., et al. (2005). Chemical toxic-
ity of indocyanine green damages
retinal pigment epithelium. Invest.
Ophthalmol. Vis. Sci. 46, 2531–2539.
doi: 10.1167/iovs.04-1521
Kassis, T. (2012). Dual-channel in-situ
optical imaging system for quan-
tifying lipid uptake and lymphatic
pump function. J. Biomed. Opt.
17:086005. doi: 10.1117/1.JBO.17.8.
086005
Kwon, S., and Sevick-Muraca, E.
M. (2010). Functional lymphatic
imaging in tumor-bearing mice.
J. Immunol. Methods 360, 167–172.
doi: 10.1016/j.jim.2010.06.016
Leu, A., Berk, D., Yuan, F., and Jain,
R. (1994). Flow velocity in the
superficial lymphatic network of
the mouse tail. Am. J. Physiol. 36,
H1507–H1513.
Levick, J. R., and Michel, C. C. (2010).
Microvascular fluid exchange and
the revised Starling principle.
Cardiovasc. Res. 87, 198–210. doi:
10.1093/cvr/cvq062
Liao, S., Cheng, G., Conner, D. A.,
Huang, Y., Kucherlapati, R. S.,
Munn, L. L., et al. (2011). Impaired
lymphatic contraction associ-
ated with immunosuppression.
Proc. Natl. Acad. Sci. U.S.A. 108,
18784–18789. doi: 10.1073/pnas.
1116152108
Nipper, M. E., and Dixon, J. B.
(2011). Engineering the lymphatic
system. Cardiovasc. Eng. Technol. 2,
296–308. doi: 10.1007/s13239-011-
0054-6
Proulx, S. T., Luciani, P., Christiansen,
A., Karaman, S., Blum, K. S.,
Rinderknecht, M., et al. (2013). Use
of a PEG-conjugated bright near-
infrared dye for functional imaging
of rerouting of tumor lymphatic
drainage after sentinel lymph
node metastasis. Biomaterials
34, 5128–5137. doi: 10.1016/j.
biomaterials.2013.03.034
Proulx, S. T., Luciani, P., Derzsi, S.,
Rinderknecht, M., Mumprecht,
V., Leroux, J.-C., et al. (2010).
Quantitative imaging of lymphatic
function with liposomal indo-
cyanine green. Cancer Res. 70,
7053–7062. doi: 10.1158/0008-
5472.CAN-10-0271
Rasmussen, J. C., Tan, I.-C., Marshall,
M. V., Fife, C. E., and Sevick-
Muraca, E. M. (2009). Lymphatic
imaging in humans with near-
infrared fluorescence. Curr. Opin.
Biotechnol. 20, 74–82. doi: 10.1016/
j.copbio.2009.01.009
Rockson, S. G. (2008). Diagnosis and
management of lymphatic vascu-
lar disease. J. Am. Coll. Cardiol. 52,
799–806. doi: 10.1016/j.jacc.2008.
06.005
Rutkowski, J. M., Moya, M., Johannes,
J., Goldman, J., and Swartz, M. A.
(2006). Secondary lymphedema in
the mouse tail: lymphatic hyper-
plasia, VEGF-C upregulation, and
the protective role of MMP-9.
Microvasc. Res. 72, 161–171. doi:
10.1016/j.mvr.2006.05.009
Scallan, J. P., and Davis, M. J. (2013).
Genetic removal of basal nitric
oxide enhances contractile activ-
ity in isolated murine collecting
lymphatic vessels. J. Physiol. 591,
2139–2156.
Sharma, R., Wendt, J. A., Rasmussen, J.
C., Adams, K. E., Marshall, M. V.,
and Sevick-Muraca, E. M. (2008).
New horizons for imaging lym-
phatic function. Ann. N.Y. Acad. Sci.
1131, 13–36. doi: 10.1196/annals.
1413.002
Swartz, M. A., Hubbell, J. A., and
Reddy, S. (2008). Lymphatic
drainage function and its
immunological implications:
from dendritic cell homing to
vaccine design. Semin. Immunol. 20,
147–156. doi: 10.1016/j.smim.2007.
11.007
Tabibiazar, R., Cheung, L., Han, J.,
Swanson, J., Beilhack, A., An, A.,
et al. (2006). Inflammatorymanifes-
tations of experimental lymphatic
insufficiency. PLoS Med. 3:e254. doi:
10.1371/journal.pmed.0030254
Tammela, T., and Alitalo, K. (2010).
Lymphangiogenesis: molecular
mechanisms and future promise.
Cell 140, 460–476. doi: 10.1016/j.
cell.2010.01.045
Unno, N., Inuzuka, K., Suzuki,
M., Yamamoto, N., Sagara, D.,
Nishiyama, M., et al. (2007).
Preliminary experience with a novel
fluorescence lymphography using
indocyanine green in patients with
secondary lymphedema. J. Vasc.
Surg. 45, 1016–1021. doi: 10.1016/j.
jvs.2007.01.023
Weber, M., Hauschild, R., Schwarz, J.,
Moussion, C., de Vries, I., Legler,
D. F., et al. (2013). Interstitial den-
dritic cell guidance by haptotac-
tic chemokine gradients. Science
339, 328–332. doi: 10.1126/science.
1228456
Weiler, M., Kassis, T., and Dixon, J. B.
(2012). Sensitivity analysis of near-
infrared functional lymphatic imag-
ing. J. Biomed. Opt. 17:066019. doi:
10.1117/1.JBO.17.6.066019
Yoon, Y.-S., Murayama, T., Gravereaux,
E., Tkebuchava, T., Silver,M., Curry,
C., et al. (2003). VEGF-C gene
therapy augments postnatal lym-
phangiogenesis and ameliorates sec-
ondary lymphedema. J. Clin. Invest.
111, 717–725.
Zampell, J. C., Elhadad, S., Avraham,
T., Weitman, E., Aschen, S., Yan,
A., et al. (2012). Toll-like receptor
deficiency worsens inflammation
and lymphedema after lymphatic
injury. Am. J. Physiol. Cell Physiol.
302, C709–C719. doi: 10.1152/
ajpcell.00284.2011
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 24 June 2013; paper pending
published: 07 July 2013; accepted: 27 July
2013; published online: 15 August 2013.
Citation: Weiler M and Dixon JB
(2013) Differential transport function of
lymphatic vessels in the rat tail model
and the long-term effects of Indocyanine
Green as assessed with near-infrared
imaging. Front. Physiol. 4:215. doi:
10.3389/fphys.2013.00215
This article was submitted to Frontiers
in Vascular Physiology, a specialty of
Frontiers in Physiology.
Copyright © 2013 Weiler and Dixon.
This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction
in other forums is permitted, provided
the original author(s) or licensor are
credited and that the original publica-
tion in this journal is cited, in accor-
dance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with
these terms.
Frontiers in Physiology | Vascular Physiology August 2013 | Volume 4 | Article 215 | 10
